REEV Secures $9.2M to Develop Wearable Robotics for Mobility-Impaired Patients

Medical technology startup REEV has successfully raised $9.2 million in a funding round aimed at advancing its innovative wearable robotic systems for individuals with mobility challenges. The round was led by Newfund Heka, Polytechnique Ventures, and Irdi Capital, with additional support from Techstars, renowned French soccer player Raphael Varane, orthopedic surgeon Dr. Herve Silbert, and a group of business angels coordinated by Scala Patrimoine.

This funding will be allocated toward the development of the company’s core products, including the wearable robotic orthosis DREEVEN and the gait analysis sensor REEV SENSE, both designed to address the needs of patients with limited mobility. The company’s expansion strategy focuses on finalizing product designs, conducting clinical trials, and ensuring compliance with regulatory requirements to enter international markets.

Bridging the Gap in Mobility Assistance

The growing demand for more adaptive, lightweight, and cost-efficient mobility solutions highlights the need for alternatives to traditional exoskeletons, which are often considered expensive, cumbersome, and limited in adaptability. REEV aims to meet these challenges by developing smarter wearable technologies that promote greater independence for patients.

Co-founder and CEO Amaury Ciurana emphasized the importance of this financial backing, stating, “With the support of our world-class partners, we are thrilled to enter the next phase of clinical and industrial development.” He added that products like DREEVEN are designed to transform mobility assistance, offering a new approach to orthotic support for patients.

Clinical Trials and Regulatory Approvals

A significant portion of the funds will be used to conduct clinical trials and secure essential approvals for market entry. The company has partnered with Boston University’s Neuromotor Recovery Lab, led by Dr. Lou Awad, to evaluate the impact of DREEVEN on patients experiencing movement disorders. The trials aim to assess the system’s effectiveness in improving mobility and enhancing the quality of life for patients with neurological conditions.

Additionally, REEV is preparing for U.S. Food and Drug Administration (FDA) trials to gain clearance for its products in the U.S. market. The company has already produced 100 commercial units of its gait analysis device REEV SENSE, which holds both FDA and CE certifications.

Innovative Wearable Solutions

Founded in 2021 by Amaury Ciurana and Dr. Robin Temporelli, REEV operates from offices in Boston, MA, and Toulouse, France. The company’s 30-person team is committed to developing cutting-edge solutions for individuals affected by mobility impairments, focusing on both personalized and adaptive technologies.

Among its key innovations is the REEV SENSE, a motion sensor that attaches to a patient’s shoe or leg and provides real-time gait analysis. The company’s flagship wearable robotic orthosis, DREEVEN, leverages electro-hydraulic technology to deliver customized knee assistance and is scheduled for market release in 2026.

Strategic Support from Leading Investors

REEV’s funding success reflects broader industry interest in deep-tech advancements in healthcare. Newfund Heka is known for its focus on brain health innovations, while Polytechnique Ventures supports startups associated with Ecole Polytechnique. Irdi Capital, through its IRDINOV3 fund, also backs deep-tech ventures with high growth potential.

Commenting on the company’s progress, Anne-Sophie Saint-Martin, partner at Newfund, said, “We are proud to continue supporting REEV as they work toward FDA clearance to bring their technology to market in the U.S. This marks a key milestone in improving mobility for neurological patients.”